SIRT1 and ovarian serous adenocarcinoma: However, in contrast, other studies showed that SIRT1 overexpression or activation resulted in acquired chemoresistance and increased invasiveness of ovarian cancer cells [8, 11], and was associated with a poorer prognosis in serous ovarian cancer patients [10].